Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

rFVIIIFc

ApprovedBiologic

BBioverativ Therapeutics Inc.

rFVIIIFc is one of 74 biologic programs targeting Hemophilia. It is currently in Approved.

3

Indications

7

Total Trials

0

Active Trials

73

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemophiliaActive, not recruiting

Hemophilia aActive, not recruiting

Severe Hemophilia aActive, not recruiting

HemophiliaPreclinical

Active, not recruiting

Hemophilia aPhase 3

Active, not recruiting

Severe Hemophilia aApproved

Active, not recruiting

Competition

Competitive Landscape

93 competitors in Hemophilia a

#DrugCompanyPhaseTrials

Hemlibra

rFVIIIFc

BBioverativ Therapeutics Inc.

Recombinant Human Coagulation FVIII

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Eptacog Alfa

Qfitlia

GGenzyme, a Sanofi Company

Valoctocogene Roxaparvovec

BioMarin Pharmaceutical

Recombinant Factor VIII

PF-06741086

Marstacimab

Rfviia

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Severe Hemophilia a3 trials

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Completed·BBioverativ, a Sanofi company·Phase 4·NCT03093480·16 enrolled

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Completed·BBioverativ, a Sanofi company·Phase 3·NCT02234323·108 enrolled

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Completed·BBioverativ Therapeutics Inc.·Phase 1·NCT01027377·16 enrolled

Tics2 trials

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

Completed·BBioverativ Therapeutics Inc.·Phase 3·NCT02502149·24 enrolled

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Completed·BBioverativ Therapeutics Inc.·Phase 1·NCT02083965·19 enrolled

Hemophilia A1 trial

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

Completed·BBioverativ Therapeutics Inc.·Phase 3·NCT01454739·240 enrolled

Hemophilia1 trial

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

Terminated·BBioverativ Therapeutics Inc.··NCT02392156·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for rFVIIIFc. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rFVIIIFc compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rFVIIIFc. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bioverativ Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: BBioverativ Therapeutics Inc.

Related News